CYAD 211
Alternative Names: Anti-BCMA CAR-T - Celyad Oncology; CYAD-211Latest Information Update: 04 Mar 2025
At a glance
- Originator Celyad Oncology
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 21 Dec 2022 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in Belgium (IV)
- 11 Dec 2021 Updated pharmacokinetics, efficacy and adverse events data from a phase I IMMUNICY-1 trial in multiple myeloma presented at the 63rd Annual Meeting and Exposition of American Society of Hematology (ASH-Hem-2021)
- 31 Jul 2021 Updated efficacy and adverse events data from a phase I IMMUNICY-1 trial in Multiple myeloma released by Celyad Oncology